{"id":4203,"date":"2020-03-27T16:03:29","date_gmt":"2020-03-27T15:03:29","guid":{"rendered":"https:\/\/patientenstimme-sma.de\/?page_id=4203"},"modified":"2026-03-16T21:04:50","modified_gmt":"2026-03-16T20:04:50","slug":"chmp-urteilt-positiv-ueber-die-zulassung-von-zolgensma-in-europa","status":"publish","type":"post","link":"https:\/\/smartunity.space\/stories\/thema\/chmp-urteilt-positiv-ueber-die-zulassung-von-zolgensma-in-europa\/","title":{"rendered":"CHMP urteilt positiv \u00fcber die Zulassung von Zolgensma\u00ae in Europa"},"content":{"rendered":"\n<p class=\"tw-text-wide\">Laut EMA Pressemitteilung gab das <a rel=\"noreferrer noopener\" aria-label=\"Committee for Medicinal Products for Human Use (\u00f6ffnet in einem neuem Tab)\" href=\"https:\/\/de.wikipedia.org\/wiki\/Ausschuss_f%C3%BCr_Humanarzneimittel\" target=\"_blank\">Committee for Medicinal Products for Human Use<\/a> heute eine positive Stellungnahme zu Zolgensma\u00ae zur Behandlung der spinalen Muskelatrophie ab.<\/p>\n\n\n\n<p class=\"tw-text-wide\">Infolge dessen wird nun die Empfehlung an die EU Kommision geschickt, welche dann, etwa in den n\u00e4chsten 2 Monaten, letztendlich die Freigabe zur Behandlung der SMA in Europa erteilt und somit Zolgensma\u00ae\u00aa nach deutschem Reglement einen Monat sp\u00e4ter in Deutschland zur Verf\u00fcgung stehen sollte.<\/p>\n\n\n\n<p class=\"tw-text-wide\">Quelle: <a rel=\"noreferrer noopener\" aria-label=\" (\u00f6ffnet in einem neuem Tab)\" href=\"https:\/\/www.ema.europa.eu\/en\/news\/new-gene-therapy-treat-spinal-muscular-atrophy\" target=\"_blank\">EMA Pressemitteilung<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Laut EMA Pressemitteilung gab das Committee for Medicinal Products for Human Use heute eine positive Stellungnahme zu Zolgensma\u00ae zur Behandlung der spinalen Muskelatrophie ab. Infolge dessen wird nun die Empfehlung an die EU Kommision geschickt, welche dann, etwa in den n\u00e4chsten 2 Monaten, letztendlich die Freigabe zur Behandlung der SMA in Europa erteilt und somit [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"only-view","format":"standard","meta":{"activitypub_content_warning":"","activitypub_content_visibility":"","activitypub_max_image_attachments":0,"activitypub_interaction_policy_quote":"anyone","activitypub_status":"","footnotes":""},"categories":[1],"tags":[58],"class_list":["post-4203","post","type-post","status-publish","format-standard","hentry","category-thema","tag-smanews"],"_links":{"self":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4203","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/comments?post=4203"}],"version-history":[{"count":1,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4203\/revisions"}],"predecessor-version":[{"id":39835,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/posts\/4203\/revisions\/39835"}],"wp:attachment":[{"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/media?parent=4203"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/categories?post=4203"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smartunity.space\/stories\/wp-json\/wp\/v2\/tags?post=4203"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}